Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAK-831 PET Study in Healthy Subjects
NCT02716987Phase 1Completed
- Sponsor
- Neurocrine Biosciences
- Start
- Mar 2016
- Primary completion
- Aug 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of luvadaxistat in Friedreich's ataxia (FA) and schizophrenia, sponsored by Neurocrine Biosciences. Primary endpoints: Total Volume of Distribution of [18F]PGM299 in the Cerebellar Grey Matter at Day 10, Non-displaceable Binding Potential of [18F]PGM299 in the Cerebellar Grey Matter at Day 10 and 1 more. Started Mar 2016; status: completed.
02
Drugs
luvadaxistat
03
Conditions
Friedreich's ataxia (FA)schizophrenia
Beyond the preview
Go deeper on NCT02716987.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02716987.